DESCRIPTION:

3rd Year Fellow talk reviewing the treatment landscape for triple-negative breast cancer and current treatment limitations, and discuss the research to identify new targets and biomarkers for triple-negative breast cancer.

 

LEARNING OBJECTIVES

  • Describe the current FDA-approved therapies for metastatic triple-negative breast cancer and limitations of approved therapies
  • Discuss the use of translational patient-derived organoid models in biomarker and therapeutic discovery research
  • Describe a novel approach leveraging metastatic drivers to identify novel protein biomarkers and therapeutic targets for triple-negative breast cancer
Session date: 
10/20/2025 - 12:00pm to 1:00pm CDT
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Please login or create an account to proceed.
Speaker Name: 
Margarite Matossian, MD, PhD